Skip to main content

Loading market data...

DGX

Quest Diagnostics Incorporated

NYSE • United states

$237.12

+$2.21

(+0.94%)

Source: Yahoo Finance · Quote time Oct 20, 2026 20:04 GMT+0000

Management
Credibility
Score

Quest Diagnostics Incorporated (DGX)

Unavailable

Quotes may be delayed

$26.17B

Market Cap

1,103,662

Volume

24.6

P/E Ratio

1.44%

Div Yield

Quest Diagnostics Incorporated Price Chart

Loading price history…

Management Credibility Analysis

Unavailable

Verified Management Score Unavailable

Management credibility requires sourced guidance and earnings history.

Upcoming Catalysts

Verified event feed

Verified Catalysts Unavailable

No sourced upcoming event feed is configured for this stock yet.

Company profile

No description available

Chief executive: Not disclosed
Headquarters: 500 PLAZA DRIVE, SECAUCUS, NJ
Founded: Not disclosed

📈 Company Timeline

Major business events

Positive

Negative

Neutral

7 Oct 2026

Quest Diagnostics Incorporated reported A director or senior management change or compensation event

Quest Diagnostics Incorporated filed an 8-K covering a director or senior management change or compensation event.

14 Aug 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in Quest Diagnostics Incorporated.

24 Jul 2026

Quest Diagnostics Incorporated filed Form 10-Q

Quest Diagnostics Incorporated submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.

23 Jul 2026

Quest Diagnostics Incorporated reported Operating or financial results

Quest Diagnostics Incorporated filed an 8-K covering operating or financial results, supporting financial statements or exhibits.

22 May 2026

Quest Diagnostics Incorporated reported Shareholder voting results

Quest Diagnostics Incorporated filed an 8-K covering shareholder voting results.

Capital Structure & Financial Position

Financial strength and liquidity analysis

Cash and equivalents (USD)$626.00M

Total assets (USD)$16.94B

Shareholders' equity (USD)$7.52B

Long-term debt (USD)$5.63B

Debt due within a year (USD)$10.00M

Source: SEC EDGAR company facts (opens in a new tab) Balance sheet dated 30 Jun 2026

Peer Comparison - Health Care

Company	Price	Market Cap
LLY - Eli Lilly and Company	$1,276.13 Yahoo Finance	$1.20T
JNJ - Johnson & Johnson	$256.74 Yahoo Finance	$618.71B
ABBV - AbbVie Inc.	$284.80 Yahoo Finance	$503.28B
UNH - UnitedHealth Group Incorporated	$418.43 Yahoo Finance	$375.58B
MRK - Merck & Co., Inc.	$148.55 Yahoo Finance	$366.50B

📋 Corporate Actions

Recent and upcoming corporate events

Verified Corporate Actions Unavailable

Dividend, buyback, split, and spin-off feeds are not ingested for this stock yet.

Financials

Financial statements and key metrics analysis

Quarter	Revenue (USD)	Operating income	Net income	Diluted EPS (USD)	Filed
Q2 2026	$3.04B	$459.00M	$320.00M	$2.84	10-Q · 23 Jul 2026
Q1 2026	$2.90B	$399.00M	$252.00M	$2.24	10-Q · 22 Apr 2026
Q4 2025	$2.81B	$386.00M	$245.00M	Unavailable	10-K · 26 Feb 2026
Q3 2025	$2.82B	$386.00M	$245.00M	$2.16	10-Q · 21 Oct 2025
Q2 2025	$2.76B	$438.00M	$282.00M	$2.47	10-Q · 23 Jul 2025
Q1 2025	$2.65B	$346.00M	$220.00M	$1.94	10-Q · 23 Apr 2025

Source: SEC EDGAR company facts (opens in a new tab)

Analyst Consensus

Buy

Target: $256.50

8.2% upside potential

📈

Strong Buy

Unavailable

👍

Buy

7

⏸️

Hold

4

📉

Sell

0

11 analysts covering this stock

Source: Nasdaq analyst research (opens in a new tab) Retrieved 21 Oct 2026, 02:48 UTC Targets range 245.00–265.00 Ratings are third-party opinions, not advice.

💰 Upcoming Dividends

Next dividend payments

Verified Dividend Data Unavailable

Dividend calendar data is not ingested for this stock yet.

Guidance Evolution

Verified Guidance History Unavailable

Verified company guidance history is not ingested for this stock yet.

💼 Director Transactions

Recent insider activity

1

Sep 2026

Davis J. E.

Director, CEO and President

Open-market sale

$242.72 per share

10,000 shares

28

Aug 2026

PREVOZNIK MICHAEL E

SVP & General Counsel

Option exercise

$112.17 per share

22,677 shares

28

Aug 2026

PREVOZNIK MICHAEL E

SVP & General Counsel

Open-market sale

$243.11 per share

22,677 shares

28

Aug 2026

PREVOZNIK MICHAEL E

SVP & General Counsel

Gift

Unavailable per share

1,000 shares

28

Jul 2026

DELANEY MARK E

SVP & Chief Commercial Officer

Open-market sale

$235.18 per share

1,600 shares

22

Jul 2026

KUPPUSAMY KARTHIK

SVP, Clinical Solutions

Other

$206.81 per share

37 shares

22

Jul 2026

CARTER ROBERT B

Director

Other

$206.80 per share

11 shares

22

Jul 2026

Gregg Vicky B

Director

Grant or award

$206.81 per share

72 shares

22

Jul 2026

Plewman Patrick

SVP for Diagnostic Services

Other

$206.81 per share

46 shares

Top Shareholders

Vanguard Group Inc

14,392,082 shares

0.986% change

12/31/2025

Blackrock, Inc.

9,275,411 shares

1.124% change

6/30/2026

Vanguard Capital Management Llc

7,233,394 shares

1.228% change

6/30/2026

Vanguard Portfolio Management Llc

6,131,045 shares

0.816% change

6/30/2026

State Street Corp

5,516,643 shares

2.524% change

6/30/2026

Price T Rowe Associates Inc /Md/

5,444,986 shares

-13.544% change

6/30/2026

Boston Partners

4,744,473 shares

18.25% change

6/30/2026

Jpmorgan Chase & Co

3,520,438 shares

-8.476% change

6/30/2026

Geode Capital Management, Llc

3,137,873 shares

1.671% change

6/30/2026

Morgan Stanley

2,460,497 shares

-0.775% change

6/30/2026

Source: Nasdaq institutional holdings (opens in a new tab) Observed 21 Oct 2026, 02:48 UTC· 1 day ago

Research coverage and investment tools

Quest Diagnostics Incorporated (DGX) is a stock listed on the New York Stock Exchange in the United States, in the Health Care sector (Medical Specialities). Its last price was US$237.12 on 20 Oct 2026. That is 85% of the way from its 52-week low of US$171.18 to its 52-week high of US$248.84. It paid US$3.38 a share in dividends over the last 12 months, a dividend yield of 1.44%. The latest ex-dividend date on file is 6 Oct 2026. Its market capitalisation was US$26.17 billion at that price.

Watch Add to portfolio Set an alert Compare Position size

How position sizing works Dividend yield and total return

Quarter	Revenue	Operating income	Net income	Diluted EPS	Gross margin	Operating margin	Free cash flow	Filed
Q2 2026	$3.04B	$459.00M	$320.00M	$2.84	—	15.1%	$459.00M	10-Q · 23 Jul 2026 (opens in a new tab)
Q1 2026	$2.90B	$399.00M	$252.00M	$2.24	—	13.8%	$164.00M	10-Q · 22 Apr 2026 (opens in a new tab)
Q4 2025	$2.81B	$386.00M	$245.00M	Unavailable	—	13.8%	$307.00M	10-K · 26 Feb 2026 (opens in a new tab)
Q3 2025	$2.82B	$386.00M	$245.00M	$2.16	—	13.7%	$419.00M	10-Q · 21 Oct 2025 (opens in a new tab)
Q2 2025	$2.76B	$438.00M	$282.00M	$2.47	—	15.9%	$436.00M	10-Q · 23 Jul 2025 (opens in a new tab)
Q1 2025	$2.65B	$346.00M	$220.00M	$1.94	—	13.0%	$197.00M	10-Q · 23 Apr 2025 (opens in a new tab)

Cash and equivalents: $626.00M
Total assets: $16.94B
Shareholders' equity: $7.52B
Long-term debt: $5.63B
Debt due within a year: $10.00M

8-K · 7 Oct 2026 · Management change

Quest Diagnostics Incorporated reported A director or senior management change or compensation event (opens in a new tab)

Quest Diagnostics Incorporated filed an 8-K covering a director or senior management change or compensation event.
SCHEDULE 13G/A · 14 Aug 2026

Large-holder ownership filing (opens in a new tab)

A holder reported or amended a beneficial ownership position of more than 5% in Quest Diagnostics Incorporated.
10-Q · 24 Jul 2026

Quest Diagnostics Incorporated filed Form 10-Q (opens in a new tab)

Quest Diagnostics Incorporated submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.
8-K · 23 Jul 2026

Quest Diagnostics Incorporated reported Operating or financial results (opens in a new tab)

Quest Diagnostics Incorporated filed an 8-K covering operating or financial results, supporting financial statements or exhibits.
8-K · 22 May 2026

Quest Diagnostics Incorporated reported Shareholder voting results (opens in a new tab)

Quest Diagnostics Incorporated filed an 8-K covering shareholder voting results.

Insider	Date	Transaction	Shares	Average price	Filing
Davis J. E. Director, CEO and President	1 Sep 2026	Open-market sale (S)	−10,000	$242.72	Form 4 (opens in a new tab)
PREVOZNIK MICHAEL E SVP & General Counsel	28 Aug 2026	Option exercise (M)	+22,677	$112.17	Form 4 (opens in a new tab)
PREVOZNIK MICHAEL E SVP & General Counsel	28 Aug 2026	Open-market sale (S)	−22,677	$243.11	Form 4 (opens in a new tab)
PREVOZNIK MICHAEL E SVP & General Counsel	28 Aug 2026	Gift (G)	−1,000	—	Form 4 (opens in a new tab)
DELANEY MARK E SVP & Chief Commercial Officer	28 Jul 2026	Open-market sale (S)	−1,600	$235.18	Form 4 (opens in a new tab)
KUPPUSAMY KARTHIK SVP, Clinical Solutions	22 Jul 2026	Other (L)	+37	$206.81	Form 4 (opens in a new tab)
CARTER ROBERT B Director	22 Jul 2026	Other (L)	+11	$206.80	Form 4 (opens in a new tab)
Gregg Vicky B Director	22 Jul 2026	Grant or award (A)	+72	$206.81	Form 4 (opens in a new tab)
Plewman Patrick SVP for Diagnostic Services	22 Jul 2026	Other (L)	+46	$206.81	Form 4 (opens in a new tab)

Institution	Report date	Shares	Change
Vanguard Group Inc	12/31/2025	14,392,082	0.986%
Blackrock, Inc.	6/30/2026	9,275,411	1.124%
Vanguard Capital Management Llc	6/30/2026	7,233,394	1.228%
Vanguard Portfolio Management Llc	6/30/2026	6,131,045	0.816%
State Street Corp	6/30/2026	5,516,643	2.524%
Price T Rowe Associates Inc /Md/	6/30/2026	5,444,986	-13.544%
Boston Partners	6/30/2026	4,744,473	18.25%
Jpmorgan Chase & Co	6/30/2026	3,520,438	-8.476%
Geode Capital Management, Llc	6/30/2026	3,137,873	1.671%
Morgan Stanley	6/30/2026	2,460,497	-0.775%

Previous close: 234.91 USD
Day range: 234.19 – 237.29 USD
52-week range: 171.18 – 248.84 USD
Volume: 1,103,662
Market cap: $26.17B
Average volume: 1,343,334
P/E ratio: 24.6
EPS (FY 2025, diluted): 8.75 USD
Dividends (last 12 months): 3.38 USD
Dividend yield: 1.44%
Ex-dividend date: 6 Oct 2026
Shares outstanding: 110.37M
Beta (5Y monthly): 0.56

Price, ranges and volume: Yahoo Finance (opens in a new tab) Observed 20 Oct 2026, 20:04 UTC· 1 day ago

Average volume and shares: Nasdaq (opens in a new tab) Observed 22 Oct 2026, 06:27 UTC· 1 hour ago

Dividends: Yahoo Finance dividend history (opens in a new tab) Observed 22 Oct 2026, 06:27 UTC· 1 hour ago

P/E is market cap ÷ trailing 12-month net income from SEC filings.

EPS: SEC EDGAR company facts (opens in a new tab)

Beta: 5 years of monthly returns against the S&P 500, calculated from Yahoo Finance prices. Market cap is the price × shares outstanding. What dividend yield leaves out: dividend yield vs total return

This research is not available for DGX yet

Guidance history

IMPORTANT FINANCIAL DISCLAIMER: The information provided on this platform is for educational and informational purposes only and should not be construed as investment advice. All investments involve risk, including potential loss of principal. Past performance does not guarantee future results. Take Profits is not a registered investment advisor and does not provide personalized investment advice. Users should conduct their own research and consult with qualified financial professionals before making investment decisions. Market data may be delayed and is provided by third-party sources.